Meeting
2018 ASCO Annual Meeting
Phase II (INSPIRE) trial of pembrolizumab (pembro) with serial immune and genomic profiling in patients (pts) with metastatic triple negative breast cancer (mTNBC).
Authors
Zachary William Neil Veitch
Princess Margaret Cancer Centre, Toronto, ON, Canada
Zachary William Neil Veitch , David W. Cescon , Sawako Elston , Scott Lien , Cindy Yang , Ben X Wang , Hal K. Berman , Marcus O. Butler , Eitan Amir , Christine Elser , Sevan Hakgor , Amanda Giesler , Trevor John Pugh , Pamela S Ohashi , Lillian L. Siu , Philippe L. Bedard
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Clinical Trial Registration Number
NCT02644369
Citation
J Clin Oncol 36, 2018 (suppl; abstr 1094)
DOI
10.1200/JCO.2018.36.15_suppl.1094
Abstract #
1094
Poster Bd #
175
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Immunologic and genomic characterization of high grade serous ovarian cancer (HGSOC) in patients (pts) treated with pembrolizumab (Pembro) in the phase II INSPIRE trial.
First Author: Ilaria Colombo
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Preliminary results from a single-arm, phase II study assessing the efficacy of pembrolizumab plus radiotherapy in metastatic triple negative breast cancer.
First Author: Alice Ho
Poster
2024 ASCO Annual Meeting
A phase II trial to assess the impact of β2 adrenergic blockade in immune checkpoint inhibitor (ICI)– refractory metastatic triple negative breast cancer (mTNBC).
First Author: Shipra Gandhi
